在Akebia Therapeutics - Usrc肾脏研究进行的中期分析揭示其药物Vafseo展现出更优越的安全性特征后,该研究已决定停止其名为VOICE的临床试验。
在Akebia Therapeutics - Usrc肾脏研究进行的中期分析揭示其药物Vafseo展现出更优越的安全性特征后,该研究已决定停止其名为VOICE的临床试验。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.